GlobeImmune, down to 6 employees, posts $1.3M quarterly loss

LOUISVILLE — Biopharma GlobeImmune Inc. (Nasdaq: GBIM) on Friday reported a net loss of $1.3 million for the quarter that ended June 30.

The Louisville-based company is down to six employees from 22, according to documents filed with the Securities and Exchange Commission, as it restructures operations to preserve cash after negative trial results of its hepatitis B drug candidate announced during the quarter.

For the quarter, GlobeImmune posted revenue of $1.3 million from collaboration license and manufacturing services compared with $1.7 million in revenue generated during the same quarter a year ago.

As of June 30, GlobeImmune had cash and cash equivalents…